Nivolumab and relatlimab for first-line treatment of unresectable or metastatic melanoma
Agency for Care Effectiveness (ACE)
Record ID 32018016080
English
Details
Project Status:
Completed
Year Published:
2026
URL for published report:
https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/nivolumab-and-relatlimab-for-first-line-treatment-of-unresectable-or-metastatic-melanoma/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Singapore
MeSH Terms
- Melanoma
- Nivolumab
- Antibodies, Monoclonal, Humanized
- Drug Combinations
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
Agency for Care Effectiveness (ACE)
Contact Address:
Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name:
ACE_HTA@moh.gov.sg
Contact Email:
ACE_HTA@moh.gov.sg
Copyright:
Agency for Care Effectiveness (ACE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.